SAN DIEGO, April 14, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2008 Annual Meeting of AACR in San Diego, CA, demonstrated that pretargeting radioimmunotherapy (RAIT) with a trivalent bispecific monoclonal antibody (bsMAb), when compared to a directly radiolabeled antibody, improved anti-tumor responses with less toxicity in a human non-Hodgkin's lymphoma model.
